» Articles » PMID: 11598041

Immunization with Components of Two Iron Uptake ABC Transporters Protects Mice Against Systemic Streptococcus Pneumoniae Infection

Overview
Journal Infect Immun
Date 2001 Oct 13
PMID 11598041
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

There has been considerable recent research into protein based Streptococcus pneumoniae vaccines as alternatives to the existing capsular antigen vaccines. PiuA and PiaA (formerly Pit1A and Pit2A) are recently identified lipoprotein components of S. pneumoniae iron uptake ABC transporters which are required for full virulence and are likely to be expressed on the surface of the bacterial cell membrane. We investigated the efficacy of recombinant PiuA and PiaA proteins at eliciting protective immunity in mice against systemic infection with S. pneumoniae. Both recombinant PiuA and PiaA generated antibody responses that cross-reacted with each other but not with pneumolysin and reacted with identical proteins from nine different S. pneumoniae serotypes. Mice immunized with recombinant PiuA and PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae. PiuA and PiaA are therefore promising additional candidates for a novel S. pneumoniae vaccine using protein antigens.

Citing Articles

serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?.

Dhawale P, Shah S, Sharma K, Sikriwal D, Kumar V, Bhagawati A Hum Vaccin Immunother. 2025; 21(1):2461844.

PMID: 39999432 PMC: 11864319. DOI: 10.1080/21645515.2025.2461844.


Unraveling the full impact of SPD_0739: a key effector in iron homeostasis.

Womack E, Antone M, Eichenbaum Z Microbiol Spectr. 2024; :e0133124.

PMID: 39470285 PMC: 11620282. DOI: 10.1128/spectrum.01331-24.


Recent progress in pneumococcal protein vaccines.

Li S, Liang H, Zhao S, Yang X, Guo Z Front Immunol. 2023; 14:1278346.

PMID: 37818378 PMC: 10560988. DOI: 10.3389/fimmu.2023.1278346.


The oxidative stress response of : its contribution to both extracellular and intracellular survival.

Hernandez-Morfa M, Olivero N, Zappia V, Pinas G, Reinoso-Vizcaino N, Cian M Front Microbiol. 2023; 14:1269843.

PMID: 37789846 PMC: 10543277. DOI: 10.3389/fmicb.2023.1269843.


Characterization and Genomic Analysis of a New Phage Infecting .

Ferreira R, Sousa C, Goncalves R, Pinheiro A, Oleastro M, Wagemans J Int J Mol Sci. 2022; 23(14).

PMID: 35887231 PMC: 9319048. DOI: 10.3390/ijms23147885.


References
1.
Wu H, Nahm M, Guo Y, Russell M, Briles D . Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis. 1997; 175(4):839-46. DOI: 10.1086/513980. View

2.
Hausdorff W, Bryant J, Paradiso P, Siber G . Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000; 30(1):100-21. DOI: 10.1086/313608. View

3.
Obaro S . Prospects for pneumococcal vaccination in African children. Acta Trop. 2000; 75(2):141-53. DOI: 10.1016/s0001-706x(99)00094-7. View

4.
Alexander J, Lock R, Peeters C, Poolman J, Andrew P, Mitchell T . Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994; 62(12):5683-8. PMC: 303321. DOI: 10.1128/iai.62.12.5683-5688.1994. View

5.
Tart R, McDaniel L, Ralph B, Briles D . Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis. 1996; 173(2):380-6. DOI: 10.1093/infdis/173.2.380. View